<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37895148</PMID><DateCompleted><Year>2023</Year><Month>10</Month><Day>30</Day></DateCompleted><DateRevised><Year>2023</Year><Month>10</Month><Day>30</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1422-0067</ISSN><JournalIssue CitedMedium="Internet"><Volume>24</Volume><Issue>20</Issue><PubDate><Year>2023</Year><Month>Oct</Month><Day>23</Day></PubDate></JournalIssue><Title>International journal of molecular sciences</Title><ISOAbbreviation>Int J Mol Sci</ISOAbbreviation></Journal><ArticleTitle>Pharmacogenomic Landscape of Ivermectin and Selective Antioxidants: Exploring Gene Interplay in the Context of Long COVID.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">15471</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/ijms242015471</ELocationID><Abstract><AbstractText>COVID-19 pandemic has caused widespread panic and fear among the global population. As such, repurposing drugs are being used as viable therapeutic options due to the limited effective treatments for Long COVID symptoms. Ivermectin is one of the emerging repurposed drugs that has been shown effective to have antiviral effects in clinical trials. In addition, antioxidant compounds are also gaining attention due to their capabilities of reducing inflammation and severity of symptoms. Due to the absence of knowledge in pharmacogenomics and modes of actions in the human body for these compounds, this study aims to provide a pharmacogenomic profile for the combination of ivermectin and six selected antioxidants (epigallocatechin gallate (EGCG), curcumin, sesamin, anthocyanins, quercetin, and N-acetylcysteine (NAC)) as potentially effective regimens for long COVID symptoms. Results showed that there were 12 interacting genes found among the ivermectin, 6 antioxidants, and COVID-19. For network pharmacology, the 12 common interacting genes/proteins had the highest associations with Pertussis pathway, AGE-RAGE signaling pathway in diabetic complications, and colorectal cancer in the Kyoto Encyclopedia of Genes and Genomes (KEGG) analyses. Disease analyses also revealed that the top three relevant diseases with COVID-19 infections were diabetes mellitus, ischemia, reperfusion injury. We also identified 6 potential target microRNAs (miRNAs) of the 12 commonly curated genes used as molecular biomarkers for COVID-19 treatments. The established pharmacogenomic network, disease analyses, and identified miRNAs could facilitate developments of effective regimens for chronic sequelae of COVID-19 especially in this post-pandemic era. However, further studies and clinical trials are needed to substantiate the effectiveness and dosages for COVID-19 treatments.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Ying-Fei</ForeName><Initials>YF</Initials><Identifier Source="ORCID">0000-0003-0304-1628</Identifier><AffiliationInfo><Affiliation>Department of Bioenvironmental Systems Engineering, National Taiwan University, Taipei 10617, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Singh</LastName><ForeName>Sher</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Life Science, School of Life Science, College of Science, National Taiwan Normal University, Taipei 11677, Taiwan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>10</Month><Day>23</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Int J Mol Sci</MedlineTA><NlmUniqueID>101092791</NlmUniqueID><ISSNLinking>1422-0067</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000975">Antioxidants</NameOfSubstance></Chemical><Chemical><RegistryNumber>70288-86-7</RegistryNumber><NameOfSubstance UI="D007559">Ivermectin</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000872">Anthocyanins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D035683">MicroRNAs</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000975" MajorTopicYN="N">Antioxidants</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007559" MajorTopicYN="N">Ivermectin</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000872" MajorTopicYN="N">Anthocyanins</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010597" MajorTopicYN="N">Pharmacogenetics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D035683" MajorTopicYN="Y">MicroRNAs</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">antioxidant compounds</Keyword><Keyword MajorTopicYN="N">disease analyses</Keyword><Keyword MajorTopicYN="N">ivermectin</Keyword><Keyword MajorTopicYN="N">long COVID</Keyword><Keyword MajorTopicYN="N">network pharmacology</Keyword><Keyword MajorTopicYN="N">pharmacogenomics</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>9</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>10</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>10</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>10</Month><Day>30</Day><Hour>6</Hour><Minute>47</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>10</Month><Day>28</Day><Hour>11</Hour><Minute>48</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>10</Month><Day>28</Day><Hour>1</Hour><Minute>20</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>10</Month><Day>23</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37895148</ArticleId><ArticleId IdType="pmc">PMC10607042</ArticleId><ArticleId IdType="doi">10.3390/ijms242015471</ArticleId><ArticleId IdType="pii">ijms242015471</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Biswas M., Sawajan N., Rungrotmongkol T., Sanachai K., Ershadian M., Sukasem C. Pharmacogenetics and Precision Medicine Approaches for the Improvement of COVID-19 Therapies. Front. Pharmacol. 2022;13:835136. doi: 10.3389/fphar.2022.835136.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphar.2022.835136</ArticleId><ArticleId IdType="pmc">PMC8894812</ArticleId><ArticleId IdType="pubmed">35250581</ArticleId></ArticleIdList></Reference><Reference><Citation>Heidary F., Gharebaghi R. Ivermectin: A systematic review from antiviral effects to COVID-19 complementary regimen. J. Antibiot. 2020;73:593&#x2013;602. doi: 10.1038/s41429-020-0336-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41429-020-0336-z</ArticleId><ArticleId IdType="pmc">PMC7290143</ArticleId><ArticleId IdType="pubmed">32533071</ArticleId></ArticleIdList></Reference><Reference><Citation>Hariyanto T.I., Halim D.A., Rosalind J., Gunawan C., Kurniawan A. Ivermectin and outcomes from COVID-19 pneumonia: A systematic review and meta-analysis of randomized clinical trial studies. Rev. Med. Virol. 2022;32:e2265. doi: 10.1002/rmv.2265.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/rmv.2265</ArticleId></ArticleIdList></Reference><Reference><Citation>L&#xf3;pez-Medina E., L&#xf3;pez P., Hurtado I.C., D&#xe1;valos D.M., Ramirez O., Mart&#xed;nez E., D&#xed;azgranados J.A., O&#xf1;ate J.M., Chavarriaga H., Herrera S., et al. Effect of Ivermectin on Time to Resolution of Symptoms among Adults with Mild COVID-19: A Randomized Clinical Trial. JAMA. 2021;325:1426&#x2013;1435. doi: 10.1001/jama.2021.3071.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2021.3071</ArticleId><ArticleId IdType="pmc">PMC7934083</ArticleId><ArticleId IdType="pubmed">33662102</ArticleId></ArticleIdList></Reference><Reference><Citation>La Maestra S., De Flora S., Balansky R. Antioxidants and COVID-19. J. Prev. Med. Hyg. 2021;62((Suppl. S3)):E34&#x2013;E45. doi: 10.15167/2421-4248/jpmh2021.62.1S3.1895.</Citation><ArticleIdList><ArticleId IdType="doi">10.15167/2421-4248/jpmh2021.62.1S3.1895</ArticleId><ArticleId IdType="pmc">PMC8452284</ArticleId><ArticleId IdType="pubmed">34622082</ArticleId></ArticleIdList></Reference><Reference><Citation>Mrityunjaya M., Pavithra V., Neelam R., Janhavi P., Halami P.M., Ravindra P.V. Immune-Boosting, Antioxidant and Anti-inflammatory Food Supplements Targeting Pathogenesis of COVID-19. Front. Immunol. 2020;11:570122. doi: 10.3389/fimmu.2020.570122.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2020.570122</ArticleId><ArticleId IdType="pmc">PMC7575721</ArticleId><ArticleId IdType="pubmed">33117359</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu J., Bodnar B.H., Meng F., Khan A.I., Wang X., Saribas S., Wang T., Lohani S.C., Wang P., Wei Z., et al. Epigallocatechin gallate from green tea effectively blocks infection of SARS-CoV-2 and new variants by inhibiting spike binding to ACE2 receptor. Cell Biosci. 2021;11:168. doi: 10.1186/s13578-021-00680-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13578-021-00680-8</ArticleId><ArticleId IdType="pmc">PMC8404181</ArticleId><ArticleId IdType="pubmed">34461999</ArticleId></ArticleIdList></Reference><Reference><Citation>Vahedian-Azimi A., Abbasifard M., Rahimi-Bashar F., Guest P.C., Majeed M., Mohammadi A., Banach M., Jamialahmadi T., Sahebkar A. Effectiveness of Curcumin on Outcomes of Hospitalized COVID-19 Patients: A Systematic Review of Clinical Trials. Nutrients. 2022;14:256. doi: 10.3390/nu14020256.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/nu14020256</ArticleId><ArticleId IdType="pmc">PMC8779570</ArticleId><ArticleId IdType="pubmed">35057437</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumar A., Mishra D.C., Angadi U.B., Yadav R., Rai A., Kumar D. Inhibition Potencies of Phytochemicals Derived from Sesame against SARS-CoV-2 Main Protease: A Molecular Docking and Simulation Study. Front. Chem. 2021;9:744376. doi: 10.3389/fchem.2021.744376.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fchem.2021.744376</ArticleId><ArticleId IdType="pmc">PMC8531729</ArticleId><ArticleId IdType="pubmed">34692642</ArticleId></ArticleIdList></Reference><Reference><Citation>Messaoudi O., Gouzi H., El-Hoshoudy A.N., Benaceur F., Patel C., Goswami D., Boukerouis D., Bendahou M. Berries anthocyanins as potential SARS-CoV&#x2013;2 inhibitors targeting the viral attachment and replication; molecular docking simulation. Egypt. J. Pet. 2021;30:33&#x2013;43. doi: 10.1016/j.ejpe.2021.01.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejpe.2021.01.001</ArticleId></ArticleIdList></Reference><Reference><Citation>Manjunath S.H., Thimmulappa R.K. Antiviral, immunomodulatory, and anticoagulant effects of quercetin and its derivatives: Potential role in prevention and management of COVID-19. J. Pharm. Anal. 2022;12:29&#x2013;34. doi: 10.1016/j.jpha.2021.09.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jpha.2021.09.009</ArticleId><ArticleId IdType="pmc">PMC8450231</ArticleId><ArticleId IdType="pubmed">34567823</ArticleId></ArticleIdList></Reference><Reference><Citation>Faverio P., Rebora P., Rossi E., Del Giudice S., Montanelli F., Garzillo L., Busnelli S., Luppi F., Valsecchi M.G., Pesci A. Impact of N-acetyl-l-cysteine on SARS-CoV-2 pneumonia and its sequelae: Results from a large cohort study. ERJ Open Res. 2022;8 doi: 10.1183/23120541.00542-2021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1183/23120541.00542-2021</ArticleId><ArticleId IdType="pmc">PMC8646003</ArticleId><ArticleId IdType="pubmed">35136824</ArticleId></ArticleIdList></Reference><Reference><Citation>Cuozzo A., Daina A., Perez M.A.S., Michielin O., Zoete V. SwissBioisostere 2021: Updated structural, bioactivity and physicochemical data delivered by a reshaped web interface. Nucleic Acids Res. 2021;50:D1382&#x2013;D1390. doi: 10.1093/nar/gkab1047.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkab1047</ArticleId><ArticleId IdType="pmc">PMC8728117</ArticleId><ArticleId IdType="pubmed">34788840</ArticleId></ArticleIdList></Reference><Reference><Citation>Heberle H., Meirelles G.V., da Silva F.R., Telles G.P., Minghim R. InteractiVenn: A web-based tool for the analysis of sets through Venn diagrams. BMC Bioinform. 2015;16:169. doi: 10.1186/s12859-015-0611-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12859-015-0611-3</ArticleId><ArticleId IdType="pmc">PMC4455604</ArticleId><ArticleId IdType="pubmed">25994840</ArticleId></ArticleIdList></Reference><Reference><Citation>Perez-Garcia L.A., Mejias-Carpio I.E., Delgado-Noguera L.A., Manzanarez-Motezuma J.P., Escalona-Rodriguez M.A., Sordillo E.M., Mogollon-Rodriguez E.A., Hernandez-Pereira C.E., Marquez-Colmenarez M.C., Paniz-Mondolfi A.E. Ivermectin: Repurposing a multipurpose drug for Venezuela&#x2019;s humanitarian crisis. Int. J. Antimicrob. Agents. 2020;56:106037. doi: 10.1016/j.ijantimicag.2020.106037.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijantimicag.2020.106037</ArticleId><ArticleId IdType="pmc">PMC7258829</ArticleId><ArticleId IdType="pubmed">32479893</ArticleId></ArticleIdList></Reference><Reference><Citation>Gonz&#xe1;lez-Paz L., Hurtado-Le&#xf3;n M.L., Lossada C., Fern&#xe1;ndez-Mater&#xe1;n F.V., Vera-Villalobos J., Loro&#xf1;o M., Paz J.L., Jeffreys L., Alvarado Y.J. Structural deformability induced in proteins of potential interest associated with COVID-19 by binding of homologues present in ivermectin: Comparative study based in elastic networks models. J. Mol. Liq. 2021;340:117284. doi: 10.1016/j.molliq.2021.117284.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molliq.2021.117284</ArticleId><ArticleId IdType="pmc">PMC8367659</ArticleId><ArticleId IdType="pubmed">34421159</ArticleId></ArticleIdList></Reference><Reference><Citation>Caly L., Druce J.D., Catton M.G., Jans D.A., Wagstaff K.M. The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antivir. Res. 2020;178:104787. doi: 10.1016/j.antiviral.2020.104787.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.antiviral.2020.104787</ArticleId><ArticleId IdType="pmc">PMC7129059</ArticleId><ArticleId IdType="pubmed">32251768</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahmed F.F., Reza M.S., Sarker M.S., Islam M.S., Mosharaf M.P., Hasan S., Mollah M.N.H. Identification of host transcriptome-guided repurposable drugs for SARS-CoV-1 infections and their validation with SARS-CoV-2 infections by using the integrated bioinformatics approaches. PLoS ONE. 2022;17:e0266124. doi: 10.1371/journal.pone.0266124.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0266124</ArticleId><ArticleId IdType="pmc">PMC8989220</ArticleId><ArticleId IdType="pubmed">35390032</ArticleId></ArticleIdList></Reference><Reference><Citation>Akinbolade S., Coughlan D., Fairbairn R., McConkey G., Powell H., Ogunbayo D., Craig D. Combination therapies for COVID-19: An overview of the clinical trials landscape. Br. J. Clin. Pharmacol. 2022;88:1590&#x2013;1597. doi: 10.1111/bcp.15089.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bcp.15089</ArticleId><ArticleId IdType="pmc">PMC8652622</ArticleId><ArticleId IdType="pubmed">34558094</ArticleId></ArticleIdList></Reference><Reference><Citation>Henss L., Auste A., Sch&#xfc;rmann C., Schmidt C., von Rhein C., M&#xfc;hlebach M.D., Schnierle B.S. The green tea catechin epigallocatechin gallate inhibits SARS-CoV-2 infection. J. Gen. Virol. 2021;102 doi: 10.1099/jgv.0.001574.</Citation><ArticleIdList><ArticleId IdType="doi">10.1099/jgv.0.001574</ArticleId><ArticleId IdType="pmc">PMC8290267</ArticleId><ArticleId IdType="pubmed">33830908</ArticleId></ArticleIdList></Reference><Reference><Citation>Jackson C.B., Farzan M., Chen B., Choe H. Mechanisms of SARS-CoV-2 entry into cells. Nat. Rev. Mol. Cell Biol. 2022;23:3&#x2013;20. doi: 10.1038/s41580-021-00418-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41580-021-00418-x</ArticleId><ArticleId IdType="pmc">PMC8491763</ArticleId><ArticleId IdType="pubmed">34611326</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y.-Q., Li Q.-S., Zheng X.-Q., Lu J.-L., Liang Y.-R. Antiviral Effects of Green Tea EGCG and Its Potential Application against COVID-19. Molecules. 2021;26:3962. doi: 10.3390/molecules26133962.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/molecules26133962</ArticleId><ArticleId IdType="pmc">PMC8271719</ArticleId><ArticleId IdType="pubmed">34209485</ArticleId></ArticleIdList></Reference><Reference><Citation>Pawar K.S., Mastud R.N., Pawar S.K., Pawar S.S., Bhoite R.R., Bhoite R.R., Kulkarni M.V., Deshpande A.R. Oral Curcumin with Piperine as Adjuvant Therapy for the Treatment of COVID-19: A Randomized Clinical Trial. Front. Pharmacol. 2021;12:1056. doi: 10.3389/fphar.2021.669362.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphar.2021.669362</ArticleId><ArticleId IdType="pmc">PMC8193734</ArticleId><ArticleId IdType="pubmed">34122090</ArticleId></ArticleIdList></Reference><Reference><Citation>Thimmulappa R.K., Mudnakudu-Nagaraju K.K., Shivamallu C., Subramaniam K.J.T., Radhakrishnan A., Bhojraj S., Kuppusamy G. Antiviral and immunomodulatory activity of curcumin: A case for prophylactic therapy for COVID-19. Heliyon. 2021;7:e06350. doi: 10.1016/j.heliyon.2021.e06350.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.heliyon.2021.e06350</ArticleId><ArticleId IdType="pmc">PMC7899028</ArticleId><ArticleId IdType="pubmed">33655086</ArticleId></ArticleIdList></Reference><Reference><Citation>Zupin L., Fontana F., Clemente L., Borelli V., Ricci G., Ruscio M., Crovella S. Optimization of Anti-SARS-CoV-2 Treatments Based on Curcumin, Used Alone or Employed as a Photosensitizer. Viruses. 2022;14:2132. doi: 10.3390/v14102132.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v14102132</ArticleId><ArticleId IdType="pmc">PMC9608677</ArticleId><ArticleId IdType="pubmed">36298687</ArticleId></ArticleIdList></Reference><Reference><Citation>Askari G., Sahebkar A., Soleimani D., Mahdavi A., Rafiee S., Majeed M., Khorvash F., Iraj B., Elyasi M., Rouhani M.H., et al. The efficacy of curcumin-piperine co-supplementation on clinical symptoms, duration, severity, and inflammatory factors in COVID-19 outpatients: A randomized double-blind, placebo-controlled trial. Trials. 2022;23:472. doi: 10.1186/s13063-022-06375-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13063-022-06375-w</ArticleId><ArticleId IdType="pmc">PMC9167899</ArticleId><ArticleId IdType="pubmed">35668500</ArticleId></ArticleIdList></Reference><Reference><Citation>Majdalawieh A.F., Yousef S.M., Abu-Yousef I.A., Nasrallah G.K. Immunomodulatory and anti-inflammatory effects of sesamin: Mechanisms of action and future directions. Crit. Rev. Food Sci. Nutr. 2022;62:5081&#x2013;5112. doi: 10.1080/10408398.2021.1881438.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/10408398.2021.1881438</ArticleId><ArticleId IdType="pubmed">33544009</ArticleId></ArticleIdList></Reference><Reference><Citation>Magurano F., Micucci M., Nuzzo D., Baggieri M., Picone P., Gioacchini S., Fioravanti R., Bucci P., Kojouri M., Mari M., et al. A potential host and virus targeting tool against COVID-19: Chemical characterization, antiviral, cytoprotective, antioxidant, respiratory smooth muscle relaxant effects of Paulownia tomentosa Steud. Biomed. Pharmacother. 2023;158:114083. doi: 10.1016/j.biopha.2022.114083.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biopha.2022.114083</ArticleId><ArticleId IdType="pmc">PMC9721285</ArticleId><ArticleId IdType="pubmed">36495668</ArticleId></ArticleIdList></Reference><Reference><Citation>Akinnusi P.A., Olubode S.O., Salaudeen W.A. Molecular binding studies of anthocyanins with multiple antiviral activities against SARS-CoV-2. Bull. Natl. Res. Cent. 2022;46:102. doi: 10.1186/s42269-022-00786-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s42269-022-00786-0</ArticleId><ArticleId IdType="pmc">PMC9006501</ArticleId><ArticleId IdType="pubmed">35431537</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Y., Zhang M., Zhang H., Qian X., Luo L., He Z. Anthocyanins Inhibit Airway Inflammation by Downregulating the NF-&#x3ba;B Pathway via the miR-138-5p/SIRT1 Axis in Asthmatic Mice. Int. Arch. Allergy Immunol. 2022;183:539&#x2013;551. doi: 10.1159/000520645.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000520645</ArticleId><ArticleId IdType="pubmed">35066501</ArticleId></ArticleIdList></Reference><Reference><Citation>Saeedi-Boroujeni A., Mahmoudian-Sani M.-R. Anti-inflammatory potential of Quercetin in COVID-19 treatment. J. Inflamm. 2021;18:3. doi: 10.1186/s12950-021-00268-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12950-021-00268-6</ArticleId><ArticleId IdType="pmc">PMC7840793</ArticleId><ArticleId IdType="pubmed">33509217</ArticleId></ArticleIdList></Reference><Reference><Citation>Di Pierro F., Iqtadar S., Khan A., Ullah Mumtaz S., Masud Chaudhry M., Bertuccioli A., Derosa G., Maffioli P., Togni S., Riva A., et al. Potential Clinical Benefits of Quercetin in the Early Stage of COVID-19: Results of a Second, Pilot, Randomized, Controlled and Open-Label Clinical Trial. Int. J. Gen. Med. 2021;14:2807&#x2013;2816. doi: 10.2147/IJGM.S318949.</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/IJGM.S318949</ArticleId><ArticleId IdType="pmc">PMC8238537</ArticleId><ArticleId IdType="pubmed">34194240</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi Z., Puyo C.A. N-Acetylcysteine to Combat COVID-19: An Evidence Review. Ther. Clin. Risk Manag. 2020;16:1047&#x2013;1055. doi: 10.2147/TCRM.S273700.</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/TCRM.S273700</ArticleId><ArticleId IdType="pmc">PMC7649937</ArticleId><ArticleId IdType="pubmed">33177829</ArticleId></ArticleIdList></Reference><Reference><Citation>Poe F.L., Corn J. N-Acetylcysteine: A potential therapeutic agent for SARS-CoV-2. Med. Hypotheses. 2020;143:109862. doi: 10.1016/j.mehy.2020.109862.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mehy.2020.109862</ArticleId><ArticleId IdType="pmc">PMC7261085</ArticleId><ArticleId IdType="pubmed">32504923</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong K.K., Lee S.W.H., Kua K.P. N-Acetylcysteine as Adjuvant Therapy for COVID-19&#x2014;A Perspective on the Current State of the Evidence. J. Inflamm. Res. 2021;14:2993&#x2013;3013. doi: 10.2147/JIR.S306849.</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/JIR.S306849</ArticleId><ArticleId IdType="pmc">PMC8274825</ArticleId><ArticleId IdType="pubmed">34262324</ArticleId></ArticleIdList></Reference><Reference><Citation>Atefi N., Behrangi E., Mozafarpoor S., Seirafianpour F., Peighambari S., Goodarzi A. N-acetylcysteine and coronavirus disease 2019: May it work as a beneficial preventive and adjuvant therapy? A comprehensive review study. J. Res. Med. Sci. 2020;25:109. doi: 10.4103/jrms.JRMS_777_20.</Citation><ArticleIdList><ArticleId IdType="doi">10.4103/jrms.JRMS_777_20</ArticleId><ArticleId IdType="pmc">PMC8019127</ArticleId><ArticleId IdType="pubmed">33824674</ArticleId></ArticleIdList></Reference><Reference><Citation>Walayat S., Shoaib H., Asghar M., Kim M., Dhillon S. Role of N-acetylcysteine in non-acetaminophen-related acute liver failure: An updated meta-analysis and systematic review. Ann. Gastroenterol. 2021;34:235&#x2013;240. doi: 10.20524/aog.2021.0571.</Citation><ArticleIdList><ArticleId IdType="doi">10.20524/aog.2021.0571</ArticleId><ArticleId IdType="pmc">PMC7903568</ArticleId><ArticleId IdType="pubmed">33654365</ArticleId></ArticleIdList></Reference><Reference><Citation>Hosseinpour A., Daneshzad E., Dezfouli R.A., Zamani S., Qorbani M. The Association Between Antioxidants and COVID-19 Outcomes: A Systematic Review on Observational Studies. Biol. Trace Elem. Res. 2023;201:5098&#x2013;5114. doi: 10.1007/s12011-023-03588-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12011-023-03588-1</ArticleId><ArticleId IdType="pmc">PMC9959932</ArticleId><ArticleId IdType="pubmed">36840911</ArticleId></ArticleIdList></Reference><Reference><Citation>Fricke-Galindo I., Falf&#xe1;n-Valencia R. Pharmacogenetics Approach for the Improvement of COVID-19 Treatment. Viruses. 2021;13:413. doi: 10.3390/v13030413.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v13030413</ArticleId><ArticleId IdType="pmc">PMC7998786</ArticleId><ArticleId IdType="pubmed">33807592</ArticleId></ArticleIdList></Reference><Reference><Citation>Takahashi T., Luzum J.A., Nicol M.R., Jacobson P.A. Pharmacogenomics of COVID-19 therapies. NPJ Genom. Med. 2020;5:35. doi: 10.1038/s41525-020-00143-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41525-020-00143-y</ArticleId><ArticleId IdType="pmc">PMC7435176</ArticleId><ArticleId IdType="pubmed">32864162</ArticleId></ArticleIdList></Reference><Reference><Citation>Chowdhury M.A., Hossain N., Kashem M.A., Shahid M.A., Alam A. Immune response in COVID-19: A review. J. Infect. Public Health. 2020;13:1619&#x2013;1629. doi: 10.1016/j.jiph.2020.07.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jiph.2020.07.001</ArticleId><ArticleId IdType="pmc">PMC7359800</ArticleId><ArticleId IdType="pubmed">32718895</ArticleId></ArticleIdList></Reference><Reference><Citation>Li X., Zhang Z., Wang Z., Guti&#xe9;rrez-Castrell&#xf3;n P., Shi H. Cell deaths: Involvement in the pathogenesis and intervention therapy of COVID-19. Signal Transduct. Target. Ther. 2022;7:186. doi: 10.1038/s41392-022-01043-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41392-022-01043-6</ArticleId><ArticleId IdType="pmc">PMC9189267</ArticleId><ArticleId IdType="pubmed">35697684</ArticleId></ArticleIdList></Reference><Reference><Citation>De Francesco E.M., Vella V., Belfiore A. COVID-19 and Diabetes: The Importance of Controlling RAGE. Front. Endocrinol. 2020;11:526. doi: 10.3389/fendo.2020.00526.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fendo.2020.00526</ArticleId><ArticleId IdType="pmc">PMC7375019</ArticleId><ArticleId IdType="pubmed">32760352</ArticleId></ArticleIdList></Reference><Reference><Citation>Matczak S., Levy C., Fortas C., Cohen J.F., B&#xe9;chet S., A&#xef;t El Belghiti F., Guillot S., Trombert-Paolantoni S., Jacomo V., Savitch Y., et al. Association between the COVID-19 pandemic and pertussis derived from multiple nationwide data sources, France, 2013 to 2020. Eurosurveillance. 2022;27:2100933. doi: 10.2807/1560-7917.ES.2022.27.25.2100933.</Citation><ArticleIdList><ArticleId IdType="doi">10.2807/1560-7917.ES.2022.27.25.2100933</ArticleId><ArticleId IdType="pmc">PMC9229195</ArticleId><ArticleId IdType="pubmed">35748301</ArticleId></ArticleIdList></Reference><Reference><Citation>Rottoli M., Gori A., Pellino G., Flacco M.E., Martellucci C., Spinelli A., Poggioli G., COVID&#x2013;Colorectal Cancer (CRC) Study Group Colorectal Cancer Stage at Diagnosis before vs during the COVID-19 Pandemic in Italy. JAMA Netw. Open. 2022;5:e2243119. doi: 10.1001/jamanetworkopen.2022.43119.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2022.43119</ArticleId><ArticleId IdType="pmc">PMC9679872</ArticleId><ArticleId IdType="pubmed">36409496</ArticleId></ArticleIdList></Reference><Reference><Citation>Attique Z., Ali A., Hamza M., al-Ghanim K.A., Mehmood A., Khan S., Ahmed Z., Al-Mulhm N., Rizwan M., Munir A., et al. In-silico network-based analysis of drugs used against COVID-19: Human well-being study. Saudi J. Biol. Sci. 2021;28:2029&#x2013;2039. doi: 10.1016/j.sjbs.2021.01.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.sjbs.2021.01.006</ArticleId><ArticleId IdType="pmc">PMC7825994</ArticleId><ArticleId IdType="pubmed">33519272</ArticleId></ArticleIdList></Reference><Reference><Citation>Lim S., Bae J.H., Kwon H.-S., Nauck M.A. COVID-19 and diabetes mellitus: From pathophysiology to clinical management. Nat. Rev. Endocrinol. 2021;17:11&#x2013;30. doi: 10.1038/s41574-020-00435-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41574-020-00435-4</ArticleId><ArticleId IdType="pmc">PMC7664589</ArticleId><ArticleId IdType="pubmed">33188364</ArticleId></ArticleIdList></Reference><Reference><Citation>Galyfos G., Sianou A., Frountzas M., Vasilios K., Vouros D., Theodoropoulos C., Michalopoulou V., Sigala F., Filis K. Acute limb ischemia among patients with COVID-19 infection. J. Vasc. Surg. 2022;75:326&#x2013;342. doi: 10.1016/j.jvs.2021.07.222.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jvs.2021.07.222</ArticleId><ArticleId IdType="pmc">PMC8358086</ArticleId><ArticleId IdType="pubmed">34390791</ArticleId></ArticleIdList></Reference><Reference><Citation>Ashraf A., Liaquat A., Shabbir S., Bokhari S.A., Tariq Z., Furrukh Z., Raja A.A., Khan M.J. High level of lactate dehydrogenase and ischaemia&#x2013;reperfusion injury regulate the multiple organ dysfunction in patients with COVID-19. Postgrad. Med. J. 2022;99:576&#x2013;581. doi: 10.1136/postgradmedj-2022-141573.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/postgradmedj-2022-141573</ArticleId><ArticleId IdType="pmc">PMC8960467</ArticleId><ArticleId IdType="pubmed">37319152</ArticleId></ArticleIdList></Reference><Reference><Citation>Farr R.J., Rootes C.L., Rowntree L.C., Nguyen T.H.O., Hensen L., Kedzierski L., Cheng A.C., Kedzierska K., Au G.G., Marsh G.A., et al. Altered microRNA expression in COVID-19 patients enables identification of SARS-CoV-2 infection. PLoS Pathog. 2021;17:e1009759. doi: 10.1371/journal.ppat.1009759.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1009759</ArticleId><ArticleId IdType="pmc">PMC8318295</ArticleId><ArticleId IdType="pubmed">34320031</ArticleId></ArticleIdList></Reference><Reference><Citation>Li C., Hu X., Li L., Li J.-H. Differential microRNA expression in the peripheral blood from human patients with COVID-19. J. Clin. Lab. Anal. 2020;34:e23590. doi: 10.1002/jcla.23590.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jcla.23590</ArticleId><ArticleId IdType="pmc">PMC7536972</ArticleId><ArticleId IdType="pubmed">32960473</ArticleId></ArticleIdList></Reference><Reference><Citation>Lou L., Tian M., Chang J., Li F., Zhang G. MiRNA-192-5p attenuates airway remodeling and autophagy in asthma by targeting MMP-16 and ATG7. Biomed. Pharmacother. 2020;122:109692. doi: 10.1016/j.biopha.2019.109692.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biopha.2019.109692</ArticleId><ArticleId IdType="pubmed">31918268</ArticleId></ArticleIdList></Reference><Reference><Citation>Bartel S., La Grutta S., Cilluffo G., Perconti G., Bongiovanni A., Giallongo A., Behrends J., Kruppa J., Hermann S., Chiang D., et al. Human airway epithelial extracellular vesicle miRNA signature is altered upon asthma development. Allergy. 2020;75:346&#x2013;356. doi: 10.1111/all.14008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/all.14008</ArticleId><ArticleId IdType="pubmed">31386204</ArticleId></ArticleIdList></Reference><Reference><Citation>Houshmandfar S., Saeedi-Boroujeni A., Rashno M., Khodadadi A., Mahmoudian-Sani M.-R. miRNA-223 as a regulator of inflammation and NLRP3 inflammasome, the main fragments in the puzzle of immunopathogenesis of different inflammatory diseases and COVID-19. Naunyn-Schmiedeberg&#x2019;s Arch. Pharmacol. 2021;394:2187&#x2013;2195. doi: 10.1007/s00210-021-02163-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00210-021-02163-6</ArticleId><ArticleId IdType="pmc">PMC8481106</ArticleId><ArticleId IdType="pubmed">34590186</ArticleId></ArticleIdList></Reference><Reference><Citation>Badary O.A. Pharmacogenomics and COVID-19: Clinical implications of human genome interactions with repurposed drugs. Pharmacogenom. J. 2021;21:275&#x2013;284. doi: 10.1038/s41397-021-00209-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41397-021-00209-9</ArticleId><ArticleId IdType="pmc">PMC7859465</ArticleId><ArticleId IdType="pubmed">33542445</ArticleId></ArticleIdList></Reference><Reference><Citation>Surendiran A., Pradhan S.C., Adithan C. Role of pharmacogenomics in drug discovery and development. Indian J. Pharmacol. 2008;40:137&#x2013;143. doi: 10.4103/0253-7613.43158.</Citation><ArticleIdList><ArticleId IdType="doi">10.4103/0253-7613.43158</ArticleId><ArticleId IdType="pmc">PMC2792612</ArticleId><ArticleId IdType="pubmed">20040945</ArticleId></ArticleIdList></Reference><Reference><Citation>Aneesh T.P., Sekhar S., Jose A., Chandran L., Zachariah S.M. Pharmacogenomics: The right drug to the right person. J. Clin. Med. Res. 2009;1:191&#x2013;194. doi: 10.4021/jocmr2009.08.1255.</Citation><ArticleIdList><ArticleId IdType="doi">10.4021/jocmr2009.08.1255</ArticleId><ArticleId IdType="pmc">PMC3299179</ArticleId><ArticleId IdType="pubmed">22461867</ArticleId></ArticleIdList></Reference><Reference><Citation>Abdullah-Koolmees H., van Keulen A.M., Nijenhuis M., Deneer V.H.M. Pharmacogenetics Guidelines: Overview and Comparison of the DPWG, CPIC, CPNDS, and RNPGx Guidelines. Front. Pharmacol. 2021;11:595219. doi: 10.3389/fphar.2020.595219.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphar.2020.595219</ArticleId><ArticleId IdType="pmc">PMC7868558</ArticleId><ArticleId IdType="pubmed">33568995</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis A.P., Wiegers T.C., Johnson R.J., Sciaky D., Wiegers J., Mattingly C.J. Comparative Toxicogenomics Database (CTD): Update 2023. Nucleic Acids Res. 2022;51:D1257&#x2013;D1262. doi: 10.1093/nar/gkac833.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkac833</ArticleId><ArticleId IdType="pmc">PMC9825590</ArticleId><ArticleId IdType="pubmed">36169237</ArticleId></ArticleIdList></Reference><Reference><Citation>Supek F., Bo&#x161;njak M., &#x160;kunca N., &#x160;muc T. REVIGO Summarizes and Visualizes Long Lists of Gene Ontology Terms. PLoS ONE. 2011;6:e21800. doi: 10.1371/journal.pone.0021800.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0021800</ArticleId><ArticleId IdType="pmc">PMC3138752</ArticleId><ArticleId IdType="pubmed">21789182</ArticleId></ArticleIdList></Reference><Reference><Citation>Kanehisa M., Furumichi M., Tanabe M., Sato Y., Morishima K. KEGG: New perspectives on genomes, pathways, diseases and drugs. Nucleic Acids Res. 2016;45:D353&#x2013;D361. doi: 10.1093/nar/gkw1092.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkw1092</ArticleId><ArticleId IdType="pmc">PMC5210567</ArticleId><ArticleId IdType="pubmed">27899662</ArticleId></ArticleIdList></Reference><Reference><Citation>Ge S.X., Jung D., Yao R. ShinyGO: A graphical gene-set enrichment tool for animals and plants. Bioinformatics. 2020;36:2628&#x2013;2629. doi: 10.1093/bioinformatics/btz931.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bioinformatics/btz931</ArticleId><ArticleId IdType="pmc">PMC7178415</ArticleId><ArticleId IdType="pubmed">31882993</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou Y., Zhou B., Pache L., Chang M., Khodabakhshi A.H., Tanaseichuk O., Benner C., Chanda S.K. Metascape provides a biologist-oriented resource for the analysis of systems-level datasets. Nat. Commun. 2019;10:1523. doi: 10.1038/s41467-019-09234-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-019-09234-6</ArticleId><ArticleId IdType="pmc">PMC6447622</ArticleId><ArticleId IdType="pubmed">30944313</ArticleId></ArticleIdList></Reference><Reference><Citation>Shannon P., Markiel A., Ozier O., Baliga N.S., Wang J.T., Ramage D., Amin N., Schwikowski B., Ideker T. Cytoscape: A software environment for integrated models of biomolecular interaction networks. Genome Res. 2003;13:2498&#x2013;2504. doi: 10.1101/gr.1239303.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/gr.1239303</ArticleId><ArticleId IdType="pmc">PMC403769</ArticleId><ArticleId IdType="pubmed">14597658</ArticleId></ArticleIdList></Reference><Reference><Citation>Bastian M., Heymann S., Jacomy M. Gephi: An Open Source Software for Exploring and Manipulating Networks; Proceedings of the International AAAI Conference on Web and Social Media; San Jose, CA, USA. 17&#x2013;20 May 2009.</Citation></Reference><Reference><Citation>Fani M., Zandi M., Ebrahimi S., Soltani S., Abbasi S. The role of miRNAs in COVID-19 disease. Future Virol. 2021;16:301&#x2013;306. doi: 10.2217/fvl-2020-0389.</Citation><ArticleIdList><ArticleId IdType="doi">10.2217/fvl-2020-0389</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang S., Amahong K., Sun X., Lian X., Liu J., Sun H., Lou Y., Zhu F., Qiu Y. The miRNA: A small but powerful RNA for COVID-19. Brief. Bioinform. 2021;22:1137&#x2013;1149. doi: 10.1093/bib/bbab062.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bib/bbab062</ArticleId><ArticleId IdType="pmc">PMC7989616</ArticleId><ArticleId IdType="pubmed">33675361</ArticleId></ArticleIdList></Reference><Reference><Citation>Quillet A., Saad C., Ferry G., Anouar Y., Vergne N., Lecroq T., Dubessy C. Improving Bioinformatics Prediction of microRNA Targets by Ranks Aggregation. Front. Genet. 2020;10:1330. doi: 10.3389/fgene.2019.01330.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fgene.2019.01330</ArticleId><ArticleId IdType="pmc">PMC6997536</ArticleId><ArticleId IdType="pubmed">32047509</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>